Acadia Healthcare Company, Inc. current report, 10 August 2015

Acadia Healthcare Company, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed on August 13, 2015, regarding an event that occurred on August 10, 2015. The filing details a secondary public offering of common stock by selling stockholders, not by the Company itself.

Key Financial Metrics

The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to the specific transaction:

  • Shares Sold: 5,033,230 shares of Common Stock.
  • Offering Price: $80.47 per share.
  • Company Proceeds: $0 (The Company will not receive any proceeds from this Offering).

Material Changes

The material change reported is the execution of an underwriting agreement with UBS Securities LLC for the sale of shares by existing stockholders. This transaction represents a dilution event for existing shareholders but does not alter the Company's capital structure or cash position directly.

Outlook, Risks, and Unusual Items

Transaction Details: The closing of the Offering is scheduled for August 14, 2015. The transaction was conducted pursuant to a prospectus supplement filed under the Company's automatic shelf registration statement (Form S-3).

Lock-Up Agreements: Directors, executive officers, and certain selling stockholders have entered into 60-day lock-up agreements restricting the sale of additional shares.

Indemnification: Acadia and the Selling Stockholders agreed to indemnify the Underwriter against certain liabilities incurred in connection with the Offering.

Investor Verification Checklist

  • Verify the identity of the "Selling Stockholders" to understand the source of the shares being sold.
  • Confirm the final closing date of August 14, 2015, and the actual number of shares sold if the offering size changes.
  • Review the full Underwriting Agreement (Exhibit 1) for specific indemnification clauses and covenants.
  • Monitor the 60-day lock-up expiration date for potential future selling pressure from insiders.